Research
Open Access
The impact of OHIP+ pharmacare on use and costs of public drug plans among children and youth in Ontario: a time-series analysis
Benard N. Miregwa, Anne Holbrook, Michael R. Law, John N. Lavis, Lehana Thabane, Lisa Dolovich and Michael G. Wilson
September 27, 2022 10 (3) E848-E855; DOI: https://doi.org/10.9778/cmajo.20210295
Benard N. Miregwa
Health Policy PhD Program (Miregwa), and Division of Clinical Pharmacology & Toxicology (Holbrook), and Department of Health Evidence and Impact (Holbrook, Lavis, Thabane, Dolovich, Wilson), McMaster University, Hamilton, Ont.; Centre for Health Services and Policy Research (Law), School of Population and Public Health, University of British Columbia, Vancouver, BC; McMaster Health Forum (Lavis, Wilson), McMaster University, Hamilton, Ont.; Leslie Dan Faculty of Pharmacy (Dolovich), University of Toronto, Toronto, Ont.; Centre for Health Economics and Policy Analysis (Wilson), McMaster University, Hamilton, Ont.
MSc MPHAnne Holbrook
Health Policy PhD Program (Miregwa), and Division of Clinical Pharmacology & Toxicology (Holbrook), and Department of Health Evidence and Impact (Holbrook, Lavis, Thabane, Dolovich, Wilson), McMaster University, Hamilton, Ont.; Centre for Health Services and Policy Research (Law), School of Population and Public Health, University of British Columbia, Vancouver, BC; McMaster Health Forum (Lavis, Wilson), McMaster University, Hamilton, Ont.; Leslie Dan Faculty of Pharmacy (Dolovich), University of Toronto, Toronto, Ont.; Centre for Health Economics and Policy Analysis (Wilson), McMaster University, Hamilton, Ont.
MD PharmDMichael R. Law
Health Policy PhD Program (Miregwa), and Division of Clinical Pharmacology & Toxicology (Holbrook), and Department of Health Evidence and Impact (Holbrook, Lavis, Thabane, Dolovich, Wilson), McMaster University, Hamilton, Ont.; Centre for Health Services and Policy Research (Law), School of Population and Public Health, University of British Columbia, Vancouver, BC; McMaster Health Forum (Lavis, Wilson), McMaster University, Hamilton, Ont.; Leslie Dan Faculty of Pharmacy (Dolovich), University of Toronto, Toronto, Ont.; Centre for Health Economics and Policy Analysis (Wilson), McMaster University, Hamilton, Ont.
PhDJohn N. Lavis
Health Policy PhD Program (Miregwa), and Division of Clinical Pharmacology & Toxicology (Holbrook), and Department of Health Evidence and Impact (Holbrook, Lavis, Thabane, Dolovich, Wilson), McMaster University, Hamilton, Ont.; Centre for Health Services and Policy Research (Law), School of Population and Public Health, University of British Columbia, Vancouver, BC; McMaster Health Forum (Lavis, Wilson), McMaster University, Hamilton, Ont.; Leslie Dan Faculty of Pharmacy (Dolovich), University of Toronto, Toronto, Ont.; Centre for Health Economics and Policy Analysis (Wilson), McMaster University, Hamilton, Ont.
MD PhDLehana Thabane
Health Policy PhD Program (Miregwa), and Division of Clinical Pharmacology & Toxicology (Holbrook), and Department of Health Evidence and Impact (Holbrook, Lavis, Thabane, Dolovich, Wilson), McMaster University, Hamilton, Ont.; Centre for Health Services and Policy Research (Law), School of Population and Public Health, University of British Columbia, Vancouver, BC; McMaster Health Forum (Lavis, Wilson), McMaster University, Hamilton, Ont.; Leslie Dan Faculty of Pharmacy (Dolovich), University of Toronto, Toronto, Ont.; Centre for Health Economics and Policy Analysis (Wilson), McMaster University, Hamilton, Ont.
PhDLisa Dolovich
Health Policy PhD Program (Miregwa), and Division of Clinical Pharmacology & Toxicology (Holbrook), and Department of Health Evidence and Impact (Holbrook, Lavis, Thabane, Dolovich, Wilson), McMaster University, Hamilton, Ont.; Centre for Health Services and Policy Research (Law), School of Population and Public Health, University of British Columbia, Vancouver, BC; McMaster Health Forum (Lavis, Wilson), McMaster University, Hamilton, Ont.; Leslie Dan Faculty of Pharmacy (Dolovich), University of Toronto, Toronto, Ont.; Centre for Health Economics and Policy Analysis (Wilson), McMaster University, Hamilton, Ont.
MSc PharmDMichael G. Wilson
Health Policy PhD Program (Miregwa), and Division of Clinical Pharmacology & Toxicology (Holbrook), and Department of Health Evidence and Impact (Holbrook, Lavis, Thabane, Dolovich, Wilson), McMaster University, Hamilton, Ont.; Centre for Health Services and Policy Research (Law), School of Population and Public Health, University of British Columbia, Vancouver, BC; McMaster Health Forum (Lavis, Wilson), McMaster University, Hamilton, Ont.; Leslie Dan Faculty of Pharmacy (Dolovich), University of Toronto, Toronto, Ont.; Centre for Health Economics and Policy Analysis (Wilson), McMaster University, Hamilton, Ont.
PhDData supplements
Online appendices
Related Articles
In this issue
Article tools
Respond to this article
The impact of OHIP+ pharmacare on use and costs of public drug plans among children and youth in Ontario: a time-series analysis
Benard N. Miregwa, Anne Holbrook, Michael R. Law, John N. Lavis, Lehana Thabane, Lisa Dolovich, Michael G. Wilson
Sep 2022, 10 (3) E848-E855; DOI: 10.9778/cmajo.20210295